Bárbara Vieira Granja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bárbara Vieira Granja has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Filomena Azevedo
Department of Dermatology and Venereology, São João Local Health Unit, Porto, Portugal
5 shared publications - Sofia Magina
Department of Dermatology and Venereology Sao Joao Local Health Unit (ULS) Porto Portugal
5 shared publications - Nuno Gomes
Department of Dermatology and Venereology Alto Minho Health Unit (ULS) Viana do Castelo Portugal
4 shared publications - Pedro Rolo De Matos
Department of Dermatology and Venereology Centro Hospitalar Universitário de São João Porto Portugal
4 shared publications - Alberto Mota
Department of Dermatology and Venereology. Unidade Local de Saúde São João. Porto. & Department of Medicine. Faculdade de Medicina. Universidade do Porto. Porto. & RISE-Health. Faculdade de Medicina. Universidade do Porto. Porto
3 shared publications - Catarina Costa
Department of Pathology Unidade Local de Saúde (ULS) São João (CHUSJ) Porto Portugal
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Real-world Outcomes of Adalimumab in Hidradenitis Suppurativa: A 10-year Retrospective Longitudinal Study
- 1 July 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessReal-world Outcomes of Adalimumab in Hidradenitis Suppurativa: A 10-year Retrospective Longitudinal Study
- 26 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1772-1774
Folliculotropic Mycosis Fungoides in a Teenager Treated With re‐ PUVA and Photodynamic Therapy
- 26 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1772-1774
Folliculotropic Mycosis Fungoides in a Teenager Treated With re‐ PUVA and Photodynamic Therapy
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real‐World Retrospective Study
Introduction: The palmoplantar region is a high‐impact area in psoriasis, with a particularly negative impact on patients’ quality of life. Tildrakizumab has shown efficacy, effectiveness, and safety in the treatment of moderate‐to‐severe plaque psoriasis but has limited evidence in high‐impact areas. The aim of this study was to retrospectively investigate the effectiveness of tildrakizumab in palmoplantar psoriasis. Methods: This was a multicentric, real‐world, retrospective study of patients with generalized psoriasis with palmoplantar involvement treated with tildrakizumab 100 mg. Patient data were collected from clinical records, and psoriasis severity was evaluated using the ppPASI, ppPASI < 3, and ppPASI < 1 as co‐primary endpoints and the PASI, PGA, BSA, and DLQI as secondary endpoints at baseline and at Weeks 28, 40, and 52 of treatment. Results: Eighteen patients were included. Mean PASI, BSA, and PGA scores showed a marked reduction from baseline (9.7 ± 6.2; 11.0 ± 7.0; 3.3 ± 0.7) to Week 28 (1.5 ± 1.3; 1.5 ± 1.5; 1.4 ± 1.1), with further improvement at Week 40 (0.9 ± 1.0; 0.9 ± 1.0; 0.9 ± 0.7) and stabilization at Week 52 (1.1 ± 2.2; 1.0 ± 1.6; 0.9 ± 1.1). DLQI scores also improved substantially from baseline (15.1 ± 3.9) to Week 28 (3.7 ± 5.4) and Week 40 (1.4 ± 2.4), with a slight increase between Week 40 and Week 52 (2.3 ± 4.3). Mean ppPASI improved from 15.4 ± 11.1 at baseline to 4.8 ± 12.0 at Week 28 and 1.2 ± 1.6 at Week 40, stabilizing at Week 52 (1.5 ± 2.7). The proportion of patients achieving absolute ppPASI < 3 and ppPASI < 1 increased consistently over time, reaching 61%, 77%, and 81% for ppPASI < 3 and 44%, 62%, and 75% for ppPASI < 1 at Weeks 28, 40, and 52, respectively. Conclusion: This study, one of the few with 52‐week real‐world data specifically in palmoplantar psoriasis, confirms that tildrakizumab is a valuable therapeutic option for the treatment of psoriasis in this location, providing effective disease control.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessTildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real‐World Retrospective Study
Introduction: The palmoplantar region is a high‐impact area in psoriasis, with a particularly negative impact on patients’ quality of life. Tildrakizumab has shown efficacy, effectiveness, and safety in the treatment of moderate‐to‐severe plaque psoriasis but has limited evidence in high‐impact areas. The aim of this study was to retrospectively investigate the effectiveness of tildrakizumab in palmoplantar psoriasis. Methods: This was a multicentric, real‐world, retrospective study of patients with generalized psoriasis with palmoplantar involvement treated with tildrakizumab 100 mg. Patient data were collected from clinical records, and psoriasis severity was evaluated using the ppPASI, ppPASI < 3, and ppPASI < 1 as co‐primary endpoints and the PASI, PGA, BSA, and DLQI as secondary endpoints at baseline and at Weeks 28, 40, and 52 of treatment. Results: Eighteen patients were included. Mean PASI, BSA, and PGA scores showed a marked reduction from baseline (9.7 ± 6.2; 11.0 ± 7.0; 3.3 ± 0.7) to Week 28 (1.5 ± 1.3; 1.5 ± 1.5; 1.4 ± 1.1), with further improvement at Week 40 (0.9 ± 1.0; 0.9 ± 1.0; 0.9 ± 0.7) and stabilization at Week 52 (1.1 ± 2.2; 1.0 ± 1.6; 0.9 ± 1.1). DLQI scores also improved substantially from baseline (15.1 ± 3.9) to Week 28 (3.7 ± 5.4) and Week 40 (1.4 ± 2.4), with a slight increase between Week 40 and Week 52 (2.3 ± 4.3). Mean ppPASI improved from 15.4 ± 11.1 at baseline to 4.8 ± 12.0 at Week 28 and 1.2 ± 1.6 at Week 40, stabilizing at Week 52 (1.5 ± 2.7). The proportion of patients achieving absolute ppPASI < 3 and ppPASI < 1 increased consistently over time, reaching 61%, 77%, and 81% for ppPASI < 3 and 44%, 62%, and 75% for ppPASI < 1 at Weeks 28, 40, and 52, respectively. Conclusion: This study, one of the few with 52‐week real‐world data specifically in palmoplantar psoriasis, confirms that tildrakizumab is a valuable therapeutic option for the treatment of psoriasis in this location, providing effective disease control.
- Open Access
- 15 May 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (10) , 1054-1055
Pyoderma Gangrenosum-Associated Autoinflammatory Syndrome With Skin Abscesses: Successful Treatment With Anti-Interleukin 1 Therapy
- 15 May 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (10) , 1054-1055
Open AccessPyoderma Gangrenosum-Associated Autoinflammatory Syndrome With Skin Abscesses: Successful Treatment With Anti-Interleukin 1 Therapy
- 13 January 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (9) , 1680-1681
VEXAS Syndrome: An Unusual Dermatological Presentation With Histiocytic Infiltration
- 13 January 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (9) , 1680-1681
VEXAS Syndrome: An Unusual Dermatological Presentation With Histiocytic Infiltration
- 7 August 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (1) , 125-128
Wells syndrome following vaccination: A pediatric case with positive patch test to gelatin
We report a 12‐month‐old boy with a skin eruption that developed 15 days after receiving the measles, mumps, rubella (MMR), pneumococcal, and meningococcal vaccines, consistent with the diagnosis of Wells syndrome. Patch testing showed a positive reaction to gelatin, which is used as a stabilizer for both live and inactivated vaccines. Gelatin was only present in the MMR vaccine.
- 7 August 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (1) , 125-128
Wells syndrome following vaccination: A pediatric case with positive patch test to gelatin
We report a 12‐month‐old boy with a skin eruption that developed 15 days after receiving the measles, mumps, rubella (MMR), pneumococcal, and meningococcal vaccines, consistent with the diagnosis of Wells syndrome. Patch testing showed a positive reaction to gelatin, which is used as a stabilizer for both live and inactivated vaccines. Gelatin was only present in the MMR vaccine.
- Open Access
- 1 July 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (4) , 642-644
Pitiríase rubra pilar após vacinação contra COVID‐19: tratamento bem‐sucedido com ustequinumabe
- 1 July 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (4) , 642-644
Open AccessPitiríase rubra pilar após vacinação contra COVID‐19: tratamento bem‐sucedido com ustequinumabe
- 23 June 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (1) , 213-215
Treatment of central centrifugal cicatricial alopecia with topical metformin 10% cream: case report and literature review
- 23 June 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (1) , 213-215
Treatment of central centrifugal cicatricial alopecia with topical metformin 10% cream: case report and literature review
- Open Access
- 22 April 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (4) , 642-644
Pityriasis rubra pilaris after COVID-19 vaccination: successful treatment with ustekinumab
- 22 April 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (4) , 642-644
Open AccessPityriasis rubra pilaris after COVID-19 vaccination: successful treatment with ustekinumab
- Open Access
- 9 February 2024
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 104, adv34750
Not Always a Malignant Tumour: A Quiz
- 9 February 2024
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 104, adv34750
Open AccessNot Always a Malignant Tumour: A Quiz